The exploitation of other signaling pathways either alone or in combination with BCR-ABL1 drugs will, sooner or later, become a reality in CML treatment to improve response, avoid resistance, and enhance treatment discontinuation probability. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.